Alprazolam extended-release in panic disorder

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1599-1611

  Rickels, Karl ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alprazolam XR; Efficacy; Panic disorder; Placebo; Safety

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; CLONAZEPAM; CYTOCHROME P450 3A4; FLUOXETINE; IMIPRAMINE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; MEMORY DISORDER; MOTOR COORDINATION; MOTOR DYSFUNCTION; NAUSEA; PANIC; PATIENT COMPLIANCE; PSYCHOMOTOR DISORDER; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ALPRAZOLAM; CLINICAL TRIALS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; PANIC DISORDER; SUBSTANCE WITHDRAWAL SYNDROME; TABLETS;

EID: 3543091606     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1599     Document Type: Article

References (63)

1. EATON WW, KESSLER RC, WITTCHEN HU, MAGEE WJ: Panic and panic disorder in the United States. Am. J. Psychiatry (1994) 151:413-420.
2. WEISSMAN MM, BLAND RC, CANINO GJ et al.: The cross-national epidemiology of panic disorder. Arch. Gen. Psychiatry (1997) 54:305-309.
3. ROBINS LN, REGIER DA: Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press, 1991.
4. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Press,Washington DC (1994).
5. SPITZER RL, WILLIAMS JB, KROENKE K et al.: Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME MD 1000 Study. JAMA (1994) 272:1749-1756.
6. SHEAR MK, SCHULBERG HC: Anxiety disorders in primary care. Bull. Menninger Clin. (1995) 59(Suppl. 2A):A73-A85.
7. TIEMENS BG, ORMEL J, SIMON GE: Occurrence, recognition, and outcome of psychological disorders in primary care. Am. J. Psychiatry (1996) 153:636-644.
8. MASSION AO, WARSHAW MG, KELLER MB: Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am. J. Psychiatry (1993) 150:600-607.
9. MARKOWITZ JS, WEISSMAN MM, OUELLETTE R et al.: Quality of life in panic disorder. Arch. Gen. Psychiatry (1989) 46:984-992.
10. KATON W, HOLLIFIELD M, CHAPMAN T et al.: Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J. Psychiatr. Res. (1995) 29:121-131.
11. SHERBOURNE CD, WELLS KB, JUDD LL: Functioning and well-being of patients with panic disorder. Am. J. Psychiatry (1996) 153:213-218.
12. LEON AC, OLFSON M, PORTERA L: Service utilization and expenditures for the treatment of panic disorder. Gen. Hosp. Psychiatry (1997) 19:82-88.
13. WANG PS, BERGLUND P, KESSLER RC: Recent care of common mental disorders in the United States: prevalence and conformance with evidence-based recommendations. J. Gen. Intern. Med. (2000) 15:284-292.
14. REES CS, RICHARDS JC, SMITH LM: Medical utilisation and costs in panic disorder: a comparison with social phobia. J. Anxiety Disord. (1998) 12:421-435.
15. BREMNER JD, INNIS RB, WHITE T et al.: SPECT [I-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol. Psychiatry (2000) 47:96-106.
16. MALIZIA AL, CUNNINGHAM VJ, BELL CJ, LIDDLE PF, JONES T, NUTT DJ: Decreased brain GABA(A)-denzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry (1998) 55:715-720.
17. KASCHKA W, FEISTEL H, EBERT D; Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J. Pychiatr. Res. (1995) 29:427-434.
18. KUIKKA JT, PITKANEN A, LEPOLA U et al.: Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl. Med. Commun. (1995) 16:273-280.
19. SCHLEGEL S, STEINERT H, BOCKISCH A, HAHN K, SCHLOESSER R, BENKERT O: Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. Eur. Arch. Psychiatry Clin. Neurosci. (1994) 244:49-51.
20. 1H-magnetic resonance spectroscopy. Arch. Gen. Psychiatry (2001) 58:556-561.
21. ROY-BYRNE PP, COWLEY DS, GREENBLATT DJ, SHADER RI, HOMMER D: Reduced benzodiazepine sensitivity in panic disorder. Arch. Gen. Psychiatry (1990) 47:534-538.
22. ROY-BYRNE P, WINGERSON DK, RADANT A, GREENBLATT DJ, COWLEY DS: Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am. J. Psychiatry (1996) 153:1444-1449.
23. CHARNEY DS: Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Pychiatr. Scand. (2003) (Suppl.):38-50.
24. CALDJI C, DIORIO J, MEANEY MJ: Variations in maternal care in infancy regulate the development of stress reactivity. Biol. Psychiatry (2000) 48:1164-1174.
25. GORMAN JM, KENT JM, SULLIVAN GM, COPLAN JD: Neuroanatomical hypothesis of panic disorder, revised. Am. J. Pychiatry (2000) 157:493-505.
26. KENT JM, MATHEW SJ, GORMAN JM: Molecular targets in the treatment of anxiety. Biol. Psychiatry (2002) 52:1008-1030.
27. KAPLAN GB, GREENBLATT DJ, EHRENBERG BL, GODDARD JE, HARMATZ JS, SHADER RI: Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J. Clin. Psychopharmacol. (2000) 20:338-346.
28. SCHWEIZER E, RICKELS K, WEISS S, ZAVODNICK S: Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch. Gen. Psychiatry (1993) 50:51-60.
29. RICKELS K, SCHWEIZER E: Panic disorder: long-term pharmacotherapy and discontinuation. J. Clin. Psychopharmacol (1998) 18(6 Suppl. 2):12S-18S.
30. LOW K, CRESTANI F, KEIST R et al.: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290:131-134.
31. WINGROVE PB, SAFO P, WHEAT L, THOMPSON SA, WAFFORD KA, WHITING PJ: Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors. Eur. J. Pharmacol. (2002) 437:31-39.
32. KRALIC JE, KORPI ER, O'BUCKLEY TK, HOMANICS GE, MORROW AL: Molecular and pharmacological characterization of GABA(A) receptor alpha1 subunit knockout mice. J. Pharmacol. Exp. Ther. (2002) 302:1037-1045.
33. KRALIC JE, O'BUCKLEY TK, KHISTI RT, HODGE CW, HOMANICS GE, MORROW AL: GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology (2002) 43:685-694.
34. RICKELS K, DOWNING R, SCHWEIZER E, HASSMAN H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry (1993) 50:884-895.
35. HOEHN-SARIC R, MCLEOD DR, ZIMMERLI WD: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J. Clin. Psychiatry (1988) 49:293-301.
36. SCHWEIZER E, RICKELS K, WEISS S, ZAVODNICK S: Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch. Gen. Psychiatry (1993) 50:51-60.
37. ROY-BYRNE PP, STANG P, WITTCHEN HU, USTUN B, WALTERS EE, KESSLER RC: Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br. J. Psychiatry (2000) 176:229-235.
38. KELLER MB, LAVORI PW, GOLDENBERG IM et al.: Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo. J. Affect. Disord. (1993) 28:27-38.
39. RICKELS K, CHUNG HR, CSANALOSI IB et al.: Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch. Gen. Psychiatry (1987) 44:862-866.
40. AMERICAN PSYCHIATRIC ASSOCIATION: Panic disorder treatment guideline. Am. J. Psychiatry (1998) 155(5 Suppl.):1-34.
41. WOODS JH, KATZ JL, WINGER G: Abuse liability of benzodiazepines. Pharmacol. Rev. (1987) 39:251-413; Erratum in: Pharmacol. Rev. (1988) 40(1):85.
42. WOODS JH, KATZ JL, WINGER G: Benzodiazepines: use, abuse and consequences. Pharmacol. Rev. (1992) 44:151-347.
43. DE WIT H, UHLENHUTH DH, EDEKER D, MCCRACKEN SG, JOHANSON CE: Lack of preference for diazepam in anxious volunteers. Arch. Gen. Pychiatry (1986) 43:553-561.
44. ROMACH M, BUSTO U, SOMER G, KAPLAN HL, SELLERS E: Clinical aspects of chronic use of alprazolam and lorazepam. Am. J. Psychiatry (1995) 152:1161-1167.
45. WRIGHT CE: Clinical pharmacokinetics of alprazolam extended release: a summary. Curr. Ther. Res. (1995) 56:947-956.
46. WRIGHT CE, SISSON TL, FLEISHAKER JC, ANTAL EJ: Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship. J. Clin. Pharmacol. (1997) 37:321-329.
47. HOSSAIN M, WRIGHT E, BAWEJA R, LUDDEN T, MILLER R: Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm. Res. (1997) 14:309-315.
48. GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, CIRAULO DA, SHADER RI: Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J. Clin. Pychiatry (1993) 54(Suppl.):4-11.
49. RARNETT-SHEEHAN K, SHEEHAN DV, RAJ BA: Speed of onset of clinical benefit of alprazolam-XR versus alprazolam-CT in panic disorder. Poster presentation at the 4th International Forum on Mood and Anxiety Disorders, Monte-Carlo, Monaco. November 19-21 (2003).
50. PRESCRIPTION RATES FOR ANXIOLYTICS: IMS MAT/Q3/1998-MAT/Q3/2003, N5C Tranquilizers Prescribed for Panic Disorder (F410), Tranquilizer Dataview Database, IMS Health, Plymouth Meeting, PA, USA.
51. BANDELOW B: Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int. Clin. Pychopharmacol. (1995) 10:73-81.
52. SHEAR MK, BROWN TA, BARLOW DH et al.: Multicenter collaborative panic disorder severity scale. Am. J. Psychiatry (1997) 154:1571-1575.
53. SCHWEIZER E, PATTERSON W, RICKELS K, ROSENTHAL M: Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am. J. Psychiatry (1993) 150:1210-1215.
54. PECKNOLD J, LUTHE L, MUNJACK D, ALEXANDER P: A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J. Clin. Pychopharmacol. (1994) 14:314-321.
55. SHEEHAN DV, RAJ AB, HARNETT-SHEEHAN K et al.: Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. Anxiety (1996) 2:40-46.
56. Pharmacia Corp.: Alprazolam-XR, US Product Information.
57. Pharmacia Corp.: Alprazolam, US Product Information.
58. GLADSJO JA, RAPAPORT MH, MCKINNEY R et al.: Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J. Clin. Pychopharmacol. (2001) 21:131-138.
59. MUMFORD GK, EVANS SM, FLEISHAKER JC, GRIFFITHS RR: Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. (1995) 57:356-365.
60. BUSTO UE, RUIZ I, BUSTO MA et al.: Benzodiazepine use in Chile: impact of availability on abuse and dependence. J. Clin. Psychopharmacol. (1996) 16:363-372.
61. ROMACH MK, BUSTO U, SOBELL LC et al.: Long-term alprazolam use: abuse, dependence or treatment. Pychopharm. Bull. (1991) 27:391-395.
62. SCHWEIZER E, RICKELS K: Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Pychiatr. Scand. Suppl. (1998) 393:95-101.
63. POLLACK MH, ALLGULANDER C, BANDELOW B et al., World Council of Anxiety: WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. (2003) 8(8 Suppl. 1):17-30.